HomeAI · summaries
Storia in 13 fonti
Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - Applied Digital (NAS
GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT, MTEN, NCRA, ZTG, EPSM, DBI, APLD. Losers include BYAH, NOTV.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
GSK in talks to buy cancer biotech Nuvalent for more than $9 billion
GSK is in negotiations to acquire cancer biotech Nuvalent for over $9 billion amid a surge in biotech mergers.
- ·
cityam.com
GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal
GSK has bought a Boston-based biopharmaceutical firm that specialises in lung cancer treatment in a $10.6bn deal.
- ·
statnews.com
GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
- ·
hindustantimes.com
UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
GSK Plc is set to acquire Nuvalent for $10.6 billion, paying $124 per share. The move aims to boost GSK's oncology treatments. | Business News
- ·
benzinga.com
Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - Applied Digital (NAS
GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT, MTEN, NCRA, ZTG, EPSM, DBI, APLD. Losers include BYAH, NOTV.
- ·
barrons.com
Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal
Nuvalent stock soars after GSK says it has agreed to buy the cancer-drug developer for $10.6 billion.
- ·
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent
GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares surge nearly 39%.
- ·
newsbytesapp.com
GSK buys US biopharma company Nuvalent for $10.6B
Britain's GSK has announced its $10.6 billion acquisition of US-based cancer-focused biopharma firm Nuvalent, paying a 40% premium at $124 per share in cash.
- ·
malaymail.com
GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent
Deal values cancer drug developer Nuvalent at US$124 (RM503) per shareThat is a 40 per cent premium to the US-listed firm’s close yesterdayGSK CEO Miels says deals expands lung...
- ·
milanofinanza.it
Nuvalent vola a Wall Street: titolo in rialzo di quasi il 40% dopo l’annuncio dell’acquisizione da 10,6 miliardi di dollari da parte di Gsk…
L’intesa prevede il lancio di un’offerta pubblica di acquisto su tutte le azioni in circolazione della società americana al prezzo di 124 dollari per azione in contanti
- ·
economictimes.indiatimes.com
$10. 6 billion deal: GSK to buy US cancer specialist Nuvalent
British pharmaceutical giant GSK has announced a massive $10.6 billion deal to acquire Nuvalent. This Boston-based company specializes in cancer treatments. The acquisition…
- ·
thisdaylive.com
GSK Boosts Cancer Portfolio, Acquires Nuvalent for $10.6 Billion
GSK Boosts Cancer Portfolio, Acquires Nuvalent for $10.6 Billion
- ·
cryptobriefing.com
GSK acquires Nuvalent for $10.6 billion to rebuild its oncology business
GSK is acquiring Nuvalent for $10.6 billion in cash, gaining three late-stage lung cancer therapies including two drugs already under FDA review.
- ·
morningstar.com
Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK
Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK